Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1 Pipeline Review, H2 2018
Summary
Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1 pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report SerineThreonine Protein Kinase Pim 1 Pipeline Review, H2 2018, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1 Protooncogene serine/threonineprotein kinase Pim1 is an enzyme encoded by the PIM1 gene. It promotes cell cycle progression and tumorigenesis by downregulating expression of a regulator of cell cycle progression CDKN1B at both transcriptional and posttranslational levels.
It mediates survival signaling through phosphorylation of BAD which induces release of the antiapoptotic protein BclX L/BCL2L1. It phosphorylation of MAP3K5, another proapoptotic protein by PIM1 significantly decreases MAP3K5 kinase activity and inhibits MAP3K5mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase3 activation and cell apoptosis The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 7 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Immunology which include indications Prostate Cancer, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Chronic Lymphocytic Leukemia CLL, Bladder Cancer, Diffuse Large BCell Lymphoma, Hematological Tumor, Lymphoma, Myocardial Infarction, NonSmall Cell Lung Carcinoma, Pancreatic Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor and Transitional Cell Carcinoma Urothelial Cell Carcinoma.
Furthermore, this report also reviews key players involved in Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1
The report reviews Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects
The report assesses Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 1 Oncogene PIM1 or PIM1 or EC 2.7.11.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope